HCA
HCA Holdings, Inc.NYSE
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Mon, May 2, 5:30 PM
  • Thu, Apr. 14, 1:36 PM
    • Morgan Stanley identifies 30 stocks for investors to snap up and hold until 2019.
    • The investment firm narrowed its list by focusing on strong brands/franchises with distinct competitive advantages, while also scoring strong on pricing power, cost efficiency, and growth.
    • The MS list includes Accenture (NYSE:ACN), Alphabet, Amazon.com, Apple, Blackstone Group (NYSE:BX),Comcast (NASDAQ:CMCSA), Constellation Brands (NYSE:STZ), CVS Health (NYSE:CVS), Danaher (NYSE:DHR), Dollar General (NYSE:DG), Estee Lauder (NYSE:EL), Facebook, First Republic Bank (NYSE:FRC), HCA Holdings (NYSE:HCA), International Business Machines (NYSE:IBM), JPMorgan Chase, L Brands (NYSE:LB), Mettler-Toledo (NYSE:MTD), NextEra Energy (NYSE:NEE), Nike (NYSE:NKE), Panera Bread (NASDAQ:PNRA), Philip Morris International (NYSE:PM), Public Storage (NYSE:PSA), Ross Stores (NASDAQ:ROST), SBA Communications(NASDAQ:SBAC), ServiceMaster (NYSE:SERV), T-Mobile (NASDAQ:TMUS), Visa (NYSE:V), WhiteWave Foods (NYSE:WWAV), and Zayo Group Holdings (NYSE:ZAYO).
    | Thu, Apr. 14, 1:36 PM | 81 Comments
  • Tue, Apr. 5, 10:28 AM
    • First Data (NYSE:FDC): "Despite its favorable debt maturity schedule (nothing due until 2018) and modest interest rate sensitivity (only approximately 1/4 of debt is floating), FDC appears to have suffered collateral damage in the recent high-yield credit market carnage. Nonetheless, we remain encouraged by FDC's positioning within the payment-processing ecosystem and continue to believe the company is well positioned to benefit from the secular trend toward electronic payments."
    • T-Mobile USA (NASDAQ:TMUS): "T-Mobile's improving cash generation coupled with ongoing subscriber momentum reinforces our outperform rating. The company appears on track for 20% EBITDA growth in 2016/17. We continue to believe TMUS's standalone story is attractive with M&A upside [long term]."
    • HCA: "We are recommending shares of HCA given strong Q4 results, a robust outlook, improved Affordable Care Act enrollment trends, and an attractive valuation. HCA's Q4 beat and bullish FY2016 outlook, released on January 29, 2016, were far in excess of expectations. Nevertheless, the stock has re-traced only a portion of its post-Q3 losses. Besides the Q3 earnings challenges, the market remains concerned with the outlook for the ACA, balance sheet leverage and mixed competitor results, but those concerns appear overblown. The stock is now trading at just 7.1x '16E EBITDA, which is a discount to the company's/industry's historical averages of 7.6x/8.6x."
    • Expedia (NASDAQ:EXPE): Expedia is "our top long-term idea. The company is well positioned to gain online-travel share from its leading travel brands, solid management execution, and strategic deployment of capital. We believe the HomeAway acquisition is highly accretive, based on leveraging HomeAway's unique inventory with Expedia's online optimization capabilities. As a result, we forecast superior earnings growth that should result in significant shareholder value, in our view."
    • FedEx (NYSE:FDX): "FedEx is lauded for its speed and service in its core FedEx Express segment, where it possesses the leading market share in 'express' parcel delivery in the U.S., as well as a strong position in its emerging FedEx Ground segment, both of which (particularly Ground) are benefiting from an e-commerce tailwind, which we estimate is driving formidable revenue growth in business-to-consumer. Anticipating a gradual economic recovery in the US/globally, we expect margin expansion via improved efficiencies and capital utilization, coupled with a realignment plan likely to meet/exceed targeting improved annual profitability of $1.65 billion by FY16."
    • CVS: "The company continues to do well in the PBM (pharmacy benefit management) segment, taking new market share ($12.7 billion net new business) while integrating the newly acquired Omnicare and Target pharmacies. We believe that CVS's focus around building solutions that span the continuum of care will resonate well with clients. Near term, the continued strength in new PBM business and acquisition synergies will likely drive the upside. CVS's focus on delivering shareholder returns in multiple avenues - earnings growth, share buybacks and dividends, makes it very attractive, especially in this turbulent market."
    • Fidelity National Information Services (NYSE:FIS): "The SunGard integration appears ahead of plan; we would not preclude upside synergies (i.e., above $200 million FY17 exit rate). FIS currently trades at approximately 14x our FY17E EPS, which we believe remains attractive."
    • Coach (NYSE:COH): "With Creative Designer Stuart Vevers' influence on full-price channel for five quarters and impact on outlet at approximately 90% this [past holiday season], we are starting to see signs of stabilization of Coach brand in North America. All in all, at 17% operating margins (31% just two years ago) and early signs of brand inflection, COH is playing better offense, despite moderation in growth of overall handbag category, and likely stands to benefit from biggest competitor KORS slowing."
    • WESCO (NYSE:WCC): "We believe WCC's hires into key strategic leadership positions in recent years support improved guidance rigor and represent a long-term investment in deeper organizational productivity potential across sales & marketing, supply chain, and IT (new CIO most recently). WCC remains positioned to drive long-term market share gains in the fragmented U.S. electrical distribution market in our view, as nonresidential and industrial capex markets recover. We note meaningful leverage to a sustained and more broad-based recovery and attractive long-term investment characteristics."
    • Anthem (NYSE:ANTM): "Overall, while the Exchanges continue to cause shorter-term pressure, we think improvements to this business, along with the potential accretion from Cigna remain attractive long-term catalysts for the company. As a result, we maintain our Outperform rating."
    • Source
    | Tue, Apr. 5, 10:28 AM | 1 Comment
  • Fri, Mar. 18, 12:56 PM
    • Vitae Pharmaceuticals (VTAE +8.2%) upgraded to Buy from Hold by Stifel. Price target set at $15 (105% upside).
    • Johnson & Johnson (JNJ +0.8%) upgraded to Overweight from Neutral by JP Morgan. Price target raised to $112 (4% upside) from $102.
    • HCA Holdings (HCA +2.8%) upgraded to Overweight from Neutral by JP Morgan. Price target raised to $85 (12% upside) from $76.
    • Epizyme (EPZM +9.8%) upgraded to Buy from Neutral by H.C. Wainwright. Price target raised to $25 (127% upside) from $22.
    • Agenus (AGEN +2.7%) upgraded to Buy from Hold with a $7 (81% upside) price target by Maxim Group.
    • Juno Therapeutics (JUNO +2.6%) upgraded to 4.5 stars (out of a possible 5.0) by the Vetr Community. The implied price target is $45.47 (17% upside).
    • Alnylam Pharmaceuticals (ALNY +3.2%) upgraded to Overweight from Neutral by JP Morgan. Price target lowered to $81 (37% upside) from $111.
    • Amicus Therapeutics (FOLD +4.3%) upgraded to Buy from Neutral by Janney Capital. Price target raised to $12 (59% upside) from $10.
    • Pernix Therapeutics Holdings (PTX -5%) downgraded to Market Perform from Outperform by Oppenheimer. $9 price target removed.
    • Valeant Pharmaceuticals (VRX -6.6%) downgraded to Neutral from Buy by Nomura. Price target lowered to $60 (116% upside) from $175. Morgan Stanley maintains Equal Weight rating but lowers price target to $39 (40% upside) from $98. Stifel rates it a Buy but lowered its price target to $65 (134% upside) from $200. Rodman & Renshaw rates it a Buy with a $118 (324% upside) price target (from $150). Piper Jaffray downgraded it to Underweight from Neutral with no price target.
    • AstraZeneca (AZN -1.5%) downgraded to Hold from Buy by Jefferies. Price target lowered to 4,350p (12% upside) from 4,900p.
    • Cardinal Health (CAH +1.4%) and McKesson (MCK +4.4%) both downgraded to Market Perform from Outperform by Cowen & Company. Price targets lowered to $90 (11% upside) and $173 (9% upside), respectively.
    | Fri, Mar. 18, 12:56 PM | 27 Comments
  • Tue, Mar. 1, 11:37 AM
    • HCA Holdings (HCA +1.3%) announces its intention to offer $1B aggregate principal amount of senior secured notes. Price, yield and terms have yet to determined. Net proceeds will be used for general corporate purposes.
    | Tue, Mar. 1, 11:37 AM
  • Wed, Feb. 10, 6:12 PM
    • Sabra Health Care REIT (SBRA +2.3%) has a deal to sell its Forest Park Medical Center Frisco Hospital to a unit of HCA, closing a chapter on a bankruptcy filing.
    • The deal is for $96.25M in cash, less assumption of capital lease obligations of about $7.3M. Columbia Medical Center of Plano, a subsidiary of HCA Holdings (HCA +1.2%), is taking on the Frisco Hospital pending a bankruptcy court hearing Feb. 18 to approve the sale.
    • Sabra's expecting to see net proceeds of $89.1M-$94.1M, and thus take a loss in Q1 of $30M-$35M on its intersts in Frisco Hospital and a debtor-in-possession loan issued to the Frisco operators.
    • HCA is up 1.6% after hours.
    | Wed, Feb. 10, 6:12 PM | 4 Comments
  • Thu, Jan. 28, 10:39 AM
    • HCA Holdings (HCA +1.8%) Q4 results: Revenues: $10,249M (+6.4%); Salaries and Benefits: $4,606M (+7.6%); Supplies: $1,686M (+1.6%); Other Operating Expense: $1,835M (+3.2%); Net Income: $582M (+10.4%); EPS: $1.40 (+17.6%); Non-GAAP EPS: $1.69 (+27.1%).
    • Q4 Operating Statistics: Reported Admissions: 467,300 (+2.0%); Equivalent Admissions: 787,800 (+3.6%); Equivalent Patient Days: 3,850,500 (+4.7%); Inpatient Surgery Cases: 134,000 (+1.1%); Outpatient Surgery Cases: 240,200 (+2.9%); Emergency Room Visits: 2,037,700 (+4.5%).
    • FY2015 results: Revenues: $39,678M (+7.5%); Salaries and Benefits: $18,115M (+8.9%); Supplies: $6,638M (+6.0%); Other Operating Expense: $7,103M (+5.2%); Net Income: $2,129M (+13.5%); EPS: $4.99 (+20.0%); Non-GAAP EPS: $5.56 (+18.3%); Quick Assets: $741M (+30.9%).
    • FY2015 Operating Statistics: Reported Admissions: 1,868,800 (+4.1%); Equivalent Admissions: 3,122,700 (+5.5%); Equivalent Patient Days: 15,299,100 (+6.7%); Inpatient Surgery Cases: 529,900 (+2.1%); Outpatient Surgery Cases: 909,400 (+2.0%); Emergency Room Visits: 8,050,200 (+8.0%).
    • 2016 Guidance: Revenues: $41.5B - 42.5B; Adjusted EBITDA: $8.15B - 8.45B; Adjusted EPS: $6.00 - 6.45; CAPEX: ~$2.7B.
    | Thu, Jan. 28, 10:39 AM
  • Thu, Jan. 28, 9:23 AM
    | Thu, Jan. 28, 9:23 AM | 16 Comments
  • Thu, Jan. 28, 8:41 AM
    • HCA Holdings (NYSE:HCA): Q4 EPS of $1.69 beats by $0.30.
    • Revenue of $10.25B (+6.3% Y/Y) beats by $90M.
    | Thu, Jan. 28, 8:41 AM | 1 Comment
  • Wed, Jan. 27, 5:30 PM
    | Wed, Jan. 27, 5:30 PM | 18 Comments
  • Mon, Jan. 11, 9:15 AM
    | Mon, Jan. 11, 9:15 AM | 2 Comments
  • Fri, Jan. 8, 5:01 PM
    • On a preliminary basis, HCA Holdings (NYSE:HCA) expects its 2015 non-GAAP EBITDA to be $7.9B, slightly higher than its guidance of $7.8B.
    • Same facility admissions, same facility equivalent admissions and same facility emergency room admissions are expected to increase 1.6%, 2.9% and 3.6%, respectively, yoy.
    • Final results will be released in the next three to four weeks.
    | Fri, Jan. 8, 5:01 PM
  • Dec. 18, 2015, 12:18 PM
    • Biogen (BIIB +0.2%) initiated with Overweight rating and $344 (16% upside) price target by Atlantic Equities.
    • CVS Health (CVS -0.1%) initiated with Overweight rating and $110 (16% upside) price target by Barclays.
    • Clovis Oncology (CLVS +0.9%) initiated with Buy rating and $50 (48% upside) price target by Janney.
    • Relypsa (RLYP +2.6%) initiated with Buy rating and $63 (123% upside) price target by H.C. Wainwright.
    • HCA Holdings (HCA -0.2%) initiated with Outperform rating and $75 (16% upside) price target; LifePoint Health (LPNT +0.4%) with an Outperform rating and $79 (13% upside) price target; Tenet Healthcare (THC +1.2%) with a Neutral rating and $33 (18% upside) price target and Universal Health Services (UHS +0.4%) with a Neutral rating and $129 (11% upside) price target by Credit Suisse.
    • Amgen (AMGN -0.1%) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $193 (20% upside) from $160.
    • Valeant Pharmaceuticals (VRX -1.8%) downgraded to Neutral from Buy by Mizuho Securities. Price target raised to $130 (19% upside) from $111.
    | Dec. 18, 2015, 12:18 PM
  • Dec. 3, 2015, 9:38 AM
    • HCA Holdings (HCA +0.6%) commences a public offering of $500M aggregate principal amount of 5.875% senior notes due 2026. The notes will trade interchangeably with the $1.0B aggregate principal amount of 5.875% senior notes due 2026 issued by the company on November 13.
    • Net proceeds will be used for general corporate purposes.
    | Dec. 3, 2015, 9:38 AM
  • Nov. 23, 2015, 2:47 PM
    • Goldman Sachs' Hedge Fund VIP list of the 50 most-heavily-owned stocks have trailed the S&P 500 by about 500 basis points (down 2% vs. the S&P's 3% gain) year-to-date, including 720 basis points of underperformance since the start of October (down about 8% vs. down about 1%).
    • Call it the Valeant effect: Health-care stocks have accounted for about 70% of the year-to-date 2% decline.
    • Based on the most recent filing, hedge funds are bailing on some of their poorer performers, including Valeant (NYSE:VRX), HCA Holdings (NYSE:HCA), Endo (NASDAQ:ENDP), Ally Financial (NYSE:ALLY), and NorthStar Realty (NYSE:NRF), and have instead placed bets on Baidu (NASDAQ:BIDU), Mylan (NASDAQ:MYL), MGM Resorts (NYSE:MGM), and GE.
    • After the shakeup, the top five hedge fund hotels: Allergan (NYSE:AGN), Facebook (NASDAQ:FB), Alphabet (GOOG, GOOGL), Time Warner Cable (NYSE:TWC), and Amazon (NASDAQ:AMZN).
    | Nov. 23, 2015, 2:47 PM | 13 Comments
  • Oct. 27, 2015, 10:29 AM
    • HCA Holdings (HCA +1.1%) Q3 results: Revenues: $9,856M (+6.9%); Salaries and Benefits: $4,619M (+9.7%); Supplies: $1,644M (+6.8%); Other Operating Expenes: $1,796M (+6.4); Adjusted EBITDA: $1,815M (-0.7%); Net Income: $449M (-13.3%); EPS: $1.05 (-9.5%); Quick Assets: $588M (+3.9%).
    • Reported Admissions: 466,400 (+3.8%); Equivalent Admissions: 787,300 (+4.8%); Revenue per Equivalent Admission: 12,517 (+2.0%); Inpatient Surgery Cases: 134,000 (+2.1%); Outpatient Surgery Cases: 226,400 (+1.7%); ER Visits: 2,023,100 (+7.2%).
    • 2015 Guidance: Non-GAAP EBITDA: ~ $7.8B; Non-GAAP EPS: $5.20 - 5.25.
    | Oct. 27, 2015, 10:29 AM